A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Phase 2

AstraZeneca

Antibodies, Monoclonal
Tremelimumab